- Home
- MAIA vs IVVD Comparison
MAIA vs IVVD Comparison
Compare MAIA & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- IVVD
- Stock Information
- Founded
- MAIA 2018
- IVVD 2020
- Country
- MAIA United States
- IVVD United States
- Employees
- MAIA N/A
- IVVD N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- IVVD Health Care
- Exchange
- MAIA Nasdaq
- IVVD Nasdaq
- Market Cap
- MAIA 56.3M
- IVVD 63.4M
- IPO Year
- MAIA 2022
- IVVD 2021
- Fundamental
- Price
- MAIA $1.59
- IVVD $1.16
- Analyst Decision
- MAIA
- IVVD Strong Buy
- Analyst Count
- MAIA 0
- IVVD 4
- Target Price
- MAIA N/A
- IVVD $3.64
- AVG Volume (30 Days)
- MAIA 375.5K
- IVVD 13.8M
- Earning Date
- MAIA 08-11-2025
- IVVD 08-14-2025
- Dividend Yield
- MAIA N/A
- IVVD N/A
- EPS Growth
- MAIA N/A
- IVVD N/A
- EPS
- MAIA N/A
- IVVD N/A
- Revenue
- MAIA N/A
- IVVD $46,210,000.00
- Revenue This Year
- MAIA N/A
- IVVD $385.94
- Revenue Next Year
- MAIA N/A
- IVVD $62.62
- P/E Ratio
- MAIA N/A
- IVVD N/A
- Revenue Growth
- MAIA N/A
- IVVD 1941.08
- 52 Week Low
- MAIA $1.40
- IVVD $0.35
- 52 Week High
- MAIA $3.74
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- MAIA 50.99
- IVVD 66.84
- Support Level
- MAIA $1.46
- IVVD $0.96
- Resistance Level
- MAIA $1.65
- IVVD $1.14
- Average True Range (ATR)
- MAIA 0.09
- IVVD 0.14
- MACD
- MAIA 0.01
- IVVD 0.05
- Stochastic Oscillator
- MAIA 43.10
- IVVD 93.12
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.